Enhanced Growth Hormone Antagonist Combinations for Targeted Cancer Therapy
Legal Citation
Summary of the Inventive Concept
This inventive concept discloses novel combinations of modified human growth hormone receptor antagonists with chemotherapeutic drugs, targeting specific cancer cells to improve treatment efficacy and reduce toxicity.
Background and Problem Solved
The original patent disclosed a composition for treating cancer using a modified human growth hormone receptor antagonist. However, the original patent had limitations in terms of targeting specific cancer cells and reducing toxicity. The new inventive concept addresses these limitations by introducing targeted combination therapies that selectively bind to cancer cells expressing predetermined levels of growth hormone receptor and prolactin receptor.
Detailed Description of the Inventive Concept
The new inventive concept comprises a system for treating cancer, wherein a modified human growth hormone receptor antagonist is combined with a chemotherapeutic drug. The antagonist is selectively targeted to cancer cells expressing predetermined levels of growth hormone receptor and prolactin receptor. The combination therapy enhances the efficacy of the chemotherapeutic drug while reducing toxicity. The antagonist can be conjugated to a polyethylene glycol molecule with a maleimide group or a branched structure, which improves its pharmacokinetics and targeting capabilities.
Novelty and Inventive Step
The new claims introduce novel combinations of modified human growth hormone receptor antagonists with chemotherapeutic drugs, which are selectively targeted to specific cancer cells. This targeting approach is new and non-obvious compared to the original patent, which did not disclose such combinations or targeting mechanisms.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept include using different chemotherapeutic drugs, modifying the polyethylene glycol molecule with different functional groups, or using different types of growth hormone receptor antagonists. These variations can be used to target different types of cancer or to improve the pharmacokinetics of the combination therapy.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the cancer treatment market, particularly in the areas of targeted therapies and combination treatments. The market for cancer treatments is growing rapidly, and this inventive concept can provide a competitive advantage in terms of efficacy and safety.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/27 |
| A | A61 | A61K45/06 |
| A | A61 | A61K47/10 |
| A | A61 | A61P35/00 |
| A | A61 | A61K2039/505 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical biotechnology, specifically cancer therapeutics and protein engineering, involving growth hormone receptor antagonists and targeted drug delivery systems
Person of Ordinary Skill (PHOSITA) Profile
A PhD-level researcher with expertise in molecular biology, protein modification techniques, cancer pharmacology, and drug conjugation strategies, familiar with protein engineering and targeted therapeutic approaches
Obviousness Rationale
A person having ordinary skill in the art would recognize that combining the growth hormone receptor antagonist with chemotherapeutic drugs represents a predictable extension of the source patent's core technology. The modifications to polyethylene glycol conjugation and selective targeting of cancer cells with specific receptor expressions are logical variations that would be apparent to a skilled researcher seeking to improve therapeutic efficacy and reduce systemic toxicity.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,602 |
|---|---|
| Title | Growth hormone antagonist and anti-cancer composition combination therapy |